I Introduction
Hypertension is a leading risk factor that contributes to the burden of global cardiovascular disease (CVD).
1,2 A related controversial but unresolved topic in CVD prevention is whether grade 1 hypertension (140-159/90-99 mmHg) with low to moderate absolute total cardiovascular risk (CVR) should be treated using anti-hypertensive drugs. 3, 4, 5, 6, 7, 8 In this consensus, total CVR is defined as follows: low as CVD mortality <1% at 10 years and moderate as CVD mortality ≥1% and <5% at 10 years according to the SCORE (Systematic Coronary Risk Estimation). 9 The elusiveness of the answers to the question posed are chiefly due to the lack of randomized clinical trials (RCT) that specifically evaluate treatment with anti-hypertensive drugs versus subgroups using placebo adjusted to the current definitions of grades of hypertension and absolute total CVR. 9, 10, 11 In addition, to be considered are i) recent results from meta-analyses, 12, 13, 14 ii) variability of clinical and psychosocial factors in subjects with grade 1 hypertension and low-moderate absolute total CVR, emphasizing the need for individualized pharmacological treatment 4 and iii) the gap between guideline recommendations and the actual treatment of hypertension in clinical practice. 15 Although basing clinical guidelines exclusively upon RCT evidence might be considered ideal, truly direct evidence-based recommendations for every clinical situation are few, and that inconsistent (or even conflicting) data must often be interpreted and extrapolated. 16, 17 Hence, on a practical basis, many trials have not adequately informed practice. 18 RCT limitations may include i) relatively small samples, ii) highly selected investigators, iii)
highly selected participants, iv) use of multiple therapies prior to randomized treatments, v) inability to answer all possible questions generated during the course of medical practice, vi) relatively short duration of controlled trials because of practical limitations-in most instances between 3 and 6 years, with an average time to an endpoint of only half of this, in order to achieve desired statistical results, vii) unwarranted extrapolation of results using one medication to the rest in its class, and viii) underrepresentation of the young, the elderly, and non-white populations. 9, 16, 17, 18 Recommendations for life-long intervention are based on considerable extrapolation from data obtained over periods much shorter than the life expectancy of most patients. Support for the belief that the benefits measured during the first few years will continue over a much longer term comes from observational studies of a few decades' duration. As a corollary, there are no criteria for duration of specific treatments during different periods in life. 9 Thus, it is necessary to create a holistic analysis of all epidemiological, clinical, psychosocial and public health elements in order to make informed and relevant decisions.
The aim of this report is to present the results of an international consultation process carried out with select experts to explore current opinions, in order to pave the way to develop clinical future guideline recommendations about the following question.
II Question guiding the consultation process
Should grade 1 hypertension with low to moderate absolute total CVR be treated with antihypertensive medication?
III Methods
The initial version of this manuscript was elaborated (by AMS) based on the latest guidelines and documents published by the major international hypertension societies, as well as several papers of interest for this consultation matter. 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 This version was sent to 55 select experts, some declined to participate. The authors, contemplate that this document could evolve as new information emerges.
IV What was recommended by the European Guidelines?
The 2013 European Guidelines recommend that the initiation of pharmacological treatment should be considered in grade 1 hypertension patients at low to moderate absolute total CVR, when blood pressure (BP) remains in this range during repeated visits, including after a reasonable trial of lifestyle modification, or is elevated by ambulatory BP criteria (Class IIa, Level B). 19 The same recommendation is considered as Class IIb, Level B by the 2016
European Guidelines on CVD Prevention. 9 The 2013 European Guidelines suggest beginning the initial control of hypertension with lifestyle changes over a few weeks alone in the following categories:
1.
Grade 1 hypertension (140-159/90-99 mmHg) and low absolute total CVR or no additional risk factors (lifestyle changes alone could be tried for a period of between 3-6 months).
2.
Grade 1 hypertension and moderate absolute total CVR (with 1 or 2 additional risk factors).
3.
Grade 1 hypertension with moderate-high absolute total CVR (with ≥ 3 risk factors).
Lowering BP with drugs should not be delayed when the patients have diabetes mellitus (DM), evidence of target organ damage, chronic kidney disease (CKD) grade ≥ 3, symptomatic CVD or grade 3 hypertension (systolic BP ≥180 mmHg and/or diastolic BP ≥ 110 mmHg).
19
European Guidelines on CVD prevention state that lifestyle measures (weight control, increased physical activity, alcohol moderation, sodium restriction in those with high consumption, and increased consumption of fruits and vegetables) are recommended in all patients with hypertension (Class I, Level A).
9
The relationship between BP and CVD morbidity and mortality is modified by the presence of other risk factors. 19, 31 The 2013 European Hypertension Guidelines recommend that decisions on treatment strategies depend on the initial level of absolute total CVR (Class I, Level B). 19 It also advises that in asymptomatic subjects with hypertension but without evidence for CVD, CKD and DM, total CVR stratification using the SCORE model is recommended as a minimal requirement (Class I, Level B). 18 In comparison, 2016
European Guidelines on CVD prevention considered systematic total CVR assessment in individuals with hypertension as Class I, Level C.

V Elements Favoring Prompt Use of Anti-Hypertensive Medications in Grade 1
Hypertension with Low-Moderate Absolute Total CVR.
Our consultation process has identified several elements that favor early antihypertensive pharmacological treatment. Those factors can be divided into four categories (Table 1) :
A. Relating to lifestyle and behavior.
1.
Avoid potential missed opportunities in primary prevention of CVD, because it is well known that after the diagnosis of hypertension a proportion of patients do not attend their next scheduled appointment; thus, their BP remains uncontrolled.
2.
Lifestyle modifications can be equivalent to drug monotherapy, but their major drawback is the low level of adherence over time. 19, 33 In clinical practice, the adherence to lifestyle changes is lower than the adherence to pharmacological treatment. Based on data in secondary prevention, the EUROASPIRE III (European Action on Secondary and Primary Prevention through Intervention to Reduce Events) study reported that body weight and physical activity targets were achieved in 18% and 34% of patients, respectively, during the period from 2006-2013. 19, 34 The degree of physical activity is often self-reported, and is higher compared with data using objective assessment methods. 35 In addition, one year after myocardial infarction, approximately 50% of hypertensive patients remained adherent to pharmacological treatment. 19 EUROASPIRE IV identified some improvements in the utilization of the pharmacological recommendations (aspirin, statins and beta-blockers) but adherence to lifestyle changes was still very low (nearly half of the participants who smoked at the time of their initial coronary event were persistent smokers and only 40% achieved a physical activity level of the recommended intensity for at least 20 minutes one or more times a week).
9,36
In general, there is a favorable global trend in control of dyslipidemia and hypertension, largely attributed to improvements in pharmacological treatment.
However, during the same time frame, there has been an increase in the prevalence of obesity and DM, two risk factors associated with an unhealthy lifestyle. 9, 37 Evidence suggests that the increase in obesity and DM are offsetting gains in morbidity and mortality due to improvements in other risk factors.
3.
Adherence to lifestyle changes might not be affordable, feasible, or effective over prolonged time periods, and does not significantly improve after the diagnosis of hypertension. 38, 39, 40 4. Non-pharmacological therapy is generally insuficient to achieve BP targets.
41
B. Relating to Total CVR
5.
CVR models have limitations. 42, 43, 44 Among others, the specificity ranges of the risk models is between 84.5 to 99.3%, but the positive predictive value ranges from 9.5 to 17.1% and the sensitivity ranges from 3.6 % to 53.4%. 42, 43, 44 Moreover, the differences between observed and expected risk levels could be significant within some risk percentiles, 45 especially when unvalidated local risk estimation systems are used. 46, 47, 48 For example, the differences on the expected average risk for a sample of Koreans subjects using the Framingham score (7.65%) and the "local" Korea score (1.67%) is substantial. 48 Recalibration of the Framingham score for the Spanish population showed that the levels of absolute total CVR should be different in Spain. 47 The predictive value of the risk models is affected by the presence of factors that are usually not included in the CVR models, such as low physical activity, obesity, being of low socioeconomic status and other psychological factors, pre-DM, a family history of premature CVD, or increased triglycerides, fibrinogen, apolipoprotein B, lipoprotein(a) levels and high-sensitivity Creactive protein. 9 In addition, it is important to point out that there are no validated tables for most low and middle income countries, where over three quarters of deaths from CVD occur. When nonrecalibrated models are applied, there has been low concordance among scores, which generates uncertainty about their utility for clinical intervention. Another unresolved controversy related to CVR models is the target of prediction, an occasionally imprecisely-defined but important variable. This is the case, for example, with total cardiovascular mortality (SCORE 9 ) or morbidity and mortality of coronary heart disease (Framingham 10 or Pooled Cohort Equations 28 ). Recently, an attempt has been made to calculate the relationship of major cardiovascular events to cardiovascular death from the data in control groups of BP-lowering RCTs. 52 The ratio was shown to decrease with the increase in cardiovascular death rate, in such a way that cardiovascular mortality should be multiplied by about 4 in individuals with cardiovascular mortality below 5% in 10 years, by about 3 when cardiovascular mortality is between 5 and 10% and by about 2 when cardiovascular mortality is above 10% to predict the rate of major cardiovascular events.
These data indicate that mortality rates may be an unprecise indicator of morbidity, particularly in younger hypertensive patients with low CVR. 52, 53, 54, 55, 56 
Risk modifiers
The presence of risk modifiers may move an individual's estimated absolute total CVR upward; absence of these modifiers should lead to lowering an individual's estimated risk. 9 There is concordance among the statements of the American College of Cardiology, 
Definition of grade 1 "isolated" hypertension
For proper CVR stratification it may be useful to define grade 1 "isolated" hypertension as patients with grade 1 uncomplicated hypertension, low (absolute and relative) total CVR and without other risk major factors and risk modifiers.
6.
Delaying pharmacological therapy increases total CVR, and ensuing risk is often not entirely reversible by treatment. 19 
7.
BP levels in mid-life are directly related to later CVR.
73
analysis of patients with grade 1 hypertension reported that BP lowering induced a significant reduction in the risk of stroke, major CVD events and all-cause mortality 12 .
Limitations of that meta analysis include a considerable proportion of individuals using background anti-hypertensive treatment at baseline, a high prevalence of participants with DM, and a high overall CVD-mortality risk of 6.2% over 10 years (above the upper < 5% cutoff for moderate total CVR according to the SCORE model). 4, 6 (new paragraph here)
Another recent meta-analysis has identified RCTs in which mean untreated baseline BP was within the grade 1 hypertension range, and found that in grade 1 hypertension with low to moderate absolute total CVR approximately 21 strokes, 34 major CVD events and 19 deaths could be prevented for every 1000 patients treated for 5 years (number needed to treat for 5 years to prevent one stroke=47, one major CVD event= 34, and one death= 19). 13 The results of this meta-analysis provides a higher level of evidence for recommendations in grade 1 hypertension with moderate CVR. 13 In this meta-analysis the CVD mortality rate of the control group was 4.5% over 10 years, 13 that is within the moderate CVR range, but above the low-risk range (<1%). Furthermore, the use of "mean" baseline values to define grade 1 hypertension cannot exclude that a minority of patients with higher BP were included, although the number of these patients is likely to be small because the average BPs were near the middle value of the range. 13 
9.
The HOPE-3 (Heart Outcomes Prevention Evaluation) RCT showed that participants with at least moderate absolute total CVR (men ≥ 55 and women ≥ 65 years of age with ≥1 CVR factors but without evidence for prior CV disease), who were in the subgroup for the upper third of systolic BP (>143.5 mm Hg) and received active treatment (hydrochlorothiazide 12.5 mg and candesartan 16 mg), had significantly lower rates of major cardiovascular outcomes than those in the placebo group. 74 The combination of these anti-hypertensive therapies with rosuvastatin (10 mg per day) was associated with the greatest reduction in CVR (40%) compared with dual placebo. 75 The benefits associated with this combination were observed in all low density lipoprotein cholesterol (LDL) 74 
10.
Two-thirds of total CVD events occur in subjects with low to moderate absolute CVR, and this proportion could be higher in women (three-quarters). In contrast, 1/3 of total CVD events occur in subjects with low absolute CVR, with considerable gender differences as well (1/4 and 1/2 in men and women, respectively). 45, 46 11. Although clinicians often require decision thresholds to trigger interventions, in a sense this is artificial, since overall risk is actually a continuum, and there is no particular point above which, for example, a drug is automatically indicated, nor below which lifestyle advice may not usefully be offered.
9,19,80,81
12.
Age clearly has the most profound influence on the calculation of the absolute total CVR. 
Age as a marker of population and individual CVR
In this context, an age of 55 years seems to be a practical and meaningful dividing line 
Relative total CVR
One of the most important elements for stratification of grade 1 hypertensive subjects with low absolute total CVR is the relative total CVR (the traditional definition uses a ratio of the absolute risk of the individual under consideration and the the average absolute risk of a baseline population, either a low-risk group or an average risk group). 64, 65 New variants of the relative CVR are a) vascular age or risk age 9, 83, 84 , b) the age and gender total CVR percentile 83 and c) long-term (eg lifetime) risk approach 28 . There is no consensus about relative CVR thresholds of low, moderate, and high risk.
The relative risk (using the traditional concept) and vascular age of the subjects represented in Figures 1 and 2 This tool can be used to improve adherence, better communicate risk, and guide pharmacological anti-hypertensive treatment decisions. However, the guidelines do not recommend the use of any relative-CVR variants for treatment decisions.
9,11,19,28
Alternatives to relative total CVR
Age-and gender-specific relative risk has been assessed from other parameters. Among them are percentile tables of coronary calcium content according to age and gender. 85, 86 MESA (Multi-Ethnic Study of Atherosclerosis) study reported that the CVR at > 90 percentile of calcium score (according to age and gender), is double than the absolute calcium > 400 Agatston units (18.9 vs 9.94, respectively). 85 
13
Individuals with a CVR factor at early ages tend to remain in rank-proportional levels of risk.
86,87
14
Simulation studies have suggested that total CVR-based blood pressure management strategies will be more cost-effective than hypertension control strategies based solely upon BP numbers, 9, 28, 42, 89, 90 but direct evidence for the role of total CVR in treatment decisions is lacking 9,91 and the best way to reduce total CVR is the control of Grade 1 hypertension with low absolute total CVR is not a benign condition. 19 Even in children and adolescents this combination is associated with increased CVR, which is reversible with treatment. 92 Grade 1 hypertension is associated with impaired arterial distensibility that improves with pharmacological treatment. 93 
16
If the success of BP lowering is measured not only by the absolute reduction in outcome it achieves, but also by the absolute level of treatment failures (residual risk) 14 , it is not surprising that the greatest success of BP lowering may be actually achieved in low-moderate risk patients. Targeting BP-lowering treatment to only those with the greatest CVR seems unwarranted because the reduction in the number of patients needing treatment to obtain a given benefit is counterbalanced by the dramatic increase in the number of patients in whom BP lowering fails to prevent fatal and nonfatal CVD events.
14
17
Gaps in knowledge exist about short-and long-term total CVR assessment and outcomes in all racial/ethnic groups, across the age spectrum, and in women and men. 
C. Relating to medical management
19
RCT demonstrate that most hypertensive patients require 2 or more drugs to achieve BP control.
19,41
20
A large number of safe anti-hypertensive medications are now available, and treatment can be personalized in order to optimize both efficacy and tolerability 19 .
Use of traditional algorithms often fails to achieve the desired hypertension control 18 , particularly in those less than 75 years of age.
96,97
22
Strategies to utilize anti-hypertensive pharmacological treatments earlier in the course of grade 1 hypertension and low-moderate absolute total CVR could have an important impact on CVD prevention and counteract physician inertia. 98 Physician inertia is considered to be one of the main causes of the low rate of BP control in modern anti-hypertensive practices, mainly in youger adults with grade 1 hypertension. 18, 99, 100 Often it is difficult to tease apart performance deficits due to insufficient treatment advancement and poor patient adherence.
23
The intensity and quality of anti-hypertensive pharmacological treatment is one of the key elements in attaining significant improvements of hypertension control as well as successful reductions in CVD mortality.
101,102
24
Although SPRINT (Systolic Blood Pressure Intervention Trial) 103 does not provide direct information on the BP level at which drug treatment should be initiated (90% of SPRINT patients were already on antihypertensive treatment at baseline). The demonstration of cardiovascular benefits in the subgroup of uncomplicated hypertensive patients with moderate total CVR, 103 may be used as indirect support favouring treatment of grade 1 hypertension.
25
High blood pressure is the leading risk factors for death in the world 104 ; and anti-hypertensive pharmacological treatment could be the most effective of cardiovascular preventive interventions (in primary and secondary prevention). 105, 106 For example, in Canada, an increase in the use of pharmacological treatment from 35% to 80%
was accompanied by significant improvements in hypertension control (13% to 68%). 102 Thus, it is often impossible to know whether individual patients in fact already have detectable cardiovascular target organ damage, or whether they have concomitant risk.
D. Relating to socio-economic and public health policies
27
A proportion of low-income patients with hypertension do not even have the resources to try favorable lifestyle changes. 22 The consumption of fruit and vegetables is inadequate worldwide, particularly in low-income countries or in less-affluent people in higher income countries, and may be attributed to both difficulty of access and unaffordability. 38 
28
Many anti-hypertensive agents are out of patent, generic, and are therefore affordable with acceptable cost-benefit ratios in high income countries. 19 Even generic drugs that are low cost in high income countries, may be relatively (compared to income) expensive in low-middle income countries unless subsidized or provided free by governments. 107 
29
The availability and affordability of healthy lifestyles could be a more signficant obstacle than for pharmacological treatment in hypertensive patients, but
improvements are needed at all levels.
38,108
The number needed to treat is a concise, epidemiologically useful presentation of the effect of an intervention in the short term , but the economic and social analysis of pharmacological treatment in young adults requires a different assessment, such as the life-years gained-to-years of potential life lost ratio. 109, 110 In addition, the quantitation of compression of morbidity and improvement in quality of life remain inexact, leaving estimation of the component of disease-free life extension an art rather than science.
109,110
31
A population-based primary prevention strategy seeks to reduce the exposure to a highly prevalent risk factor for disease. 111 The effect of current population strategies for BP reduction has done little to decrease population systolic BP mean and hypertension prevalence. 111 European Guidelines on CVD prevention state that scientific evidence of the impact of food and nutrition policy instruments on outcome measures such as food intake and cardiovascular health is lacking. 9 Cost-effectiveness studies of the impact of different policy options are also limited.  Non-pharmacological therapy is generally insufficient to reach BP targets.
Relating to Total CVR

Predictions using CVR models have limitations.
 Delaying pharmacological therapy increases total CVR.
 Two-thirds of CVD events occur in subjects with low to moderate absolute total CVR.
 Direct evidence for the role of total CVR in treatment decisions is lacking.
 Individuals with a CVR factor at early ages tend to remain at rank-proportional levels of risk.
 Grade 1 hypertension with low to moderate absolute total CVR is not a benign condition.
Most physicians rarely or never use total CVR models.
 Assessment of relative CVR may be a key risk modifier in younger hypertensive adults, but there is currently no consensus on relative CVR thresholds.
Relating to medical management  Most hypertensive patients require 2 or more drugs to achieve BP control. Relating to socio-economic and public health policies  The availability and affordability of healthy lifestyle could be a greater obstacle than for pharmacological treatment.
The economic and social analyses of pharmacological treatment in young adults require calculation of the life-years gained-to-years of potential life lost ratio.
VI Final considerations
A. Individual 19 and population interventions 112, 113 are not opposing, but synergistic strategies; hypertension management should always take into account the balance between clinical and the public health approaches, an issue particularly relevant for low-middle income countries. 24, 26, 27, 114 The cost perspective is a critical component of this balance, because governments and individuals need to prioritize how their limited funds are best spent. 9, 24, 26, 27 B. This consultation, properly aligned with current global context of the cardiovascular prevention comes at a unique time in hypertension management philosophy and approach. 9, 24, 26, 27, 115, 116, 117, 118 Indeed, several relevant partners led by the HEARTS. 24 The HEARTS technical package covers six elements: healthy lifestyle (counsel on CVR factors and self-care), evidence-based treatment protocols (simple and standardized protocols), access to essential medicines and technology (a core set of affordable medicines and basic technologies), risk-based management (total cardiovascular risk assessment, treatment and referral), team care and task-sharing (patient-centered care through a team approach and community participation), and systems for monitoring (patient and programme monitoring and evaluation). 24 This global initiative is promoting a set of needed major system changes within the delivery of health care to achieve improvements in hypertension control. 24 Therefore, this consultation, properly aligned with this new context of the approach to hypertension management, can pave the way to develop a more innovative clinical recommendations in the near future. Our attainable goal is a practical and standardized algorithm to raise the quality of medical care of patients with hypertension and hence, improve control and outcomes. 24, 26, 27 
VII Key conclusions
This consultation process reached the following consensus in hypertensive adults aged < 80 years (Table 2 ).
1.
The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 "isolated" hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other risk major factors and risk modifiers).
2.
The initiation of anti-hypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. 
